These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 26397731)

  • 21. The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable.
    Afzali A; Furtner D; Melsheimer R; Molloy PJ
    Adv Ther; 2021 May; 38(5):2077-2093. PubMed ID: 33745111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biosimilars: Implications for health-system pharmacists.
    Lucio SD; Stevenson JG; Hoffman JM
    Am J Health Syst Pharm; 2013 Nov; 70(22):2004-17. PubMed ID: 24173009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.
    Declerck P; Danesi R; Petersel D; Jacobs I
    Drugs; 2017 Apr; 77(6):671-677. PubMed ID: 28258517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Approval Process: An Overview of Biosimilars in the Oncology Setting.
    Sowinski-Raff L
    Clin J Oncol Nurs; 2018 Oct; 22(5):13-18. PubMed ID: 30239527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biosimilars: A Multidisciplinary Perspective.
    Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
    Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postmarketing Safety of Biosimilars: Current Status, Challenges, and Opportunities in the Spontaneous Reporting System.
    Singh A; Kalaivani M; Srivastava S; Goyal RK; Gupta SK
    Ther Innov Regul Sci; 2020 May; 54(3):667-680. PubMed ID: 33301154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.
    Pivot X; Aulagner G; Blay JY; Fumoleau P; Kaliski A; Sarkozy F; Limat S
    Anticancer Drugs; 2015 Nov; 26(10):1009-16. PubMed ID: 26352219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biosimilars: the need, the challenge, the future: the FDA perspective.
    Epstein MS; Ehrenpreis ED; Kulkarni PM;
    Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Introduction of Biosimilar Therapeutics Into Nephrology Practice in the United States: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
    Wish JB; Charytan C; Chertow GM; Kalantar-Zadeh K; Kliger AS; Rubin RJ; Yee J; Fishbane S
    Am J Kidney Dis; 2016 Dec; 68(6):843-852. PubMed ID: 27599628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Regulation of Biosimilars in Latin America.
    Garcia R; Araujo DV
    Curr Rheumatol Rep; 2016 Mar; 18(3):16. PubMed ID: 26951254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution.
    Druedahl LC; Kälvemark Sporrong S; Minssen T; Hoogland H; De Bruin ML; van de Weert M; Almarsdóttir AB
    PLoS One; 2022; 17(1):e0262537. PubMed ID: 35015783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Developing clinical trials for biosimilars.
    Bui LA; Taylor C
    Semin Oncol; 2014 Feb; 41 Suppl 1():S15-25. PubMed ID: 24560024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America.
    de la Cruz C; de Carvalho AV; Dorantes GL; Londoño Garcia AM; Gonzalez C; Maskin M; Podoswa N; Redfern JS; Valenzuela F; van der Walt J; Romiti R
    J Dermatol; 2017 Jan; 44(1):3-12. PubMed ID: 27461455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDA Biosimilar Action Plan: could improving pharmacovigilance of biologics improve patient and physician confidence in biosimilars?
    Jordan JB; Christl L
    Expert Opin Drug Saf; 2020 Mar; 19(3):229-232. PubMed ID: 32098520
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical data and regulatory issues of biosimilar products.
    Stevenson JG
    Am J Manag Care; 2015 Dec; 21(16 Suppl):s320-30. PubMed ID: 26788808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biosimilars: current scientific and regulatory considerations.
    Chugh PK; Roy V
    Curr Clin Pharmacol; 2014 Feb; 9(1):53-63. PubMed ID: 23952143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drift, evolution, and divergence in biologics and biosimilars manufacturing.
    Ramanan S; Grampp G
    BioDrugs; 2014 Aug; 28(4):363-72. PubMed ID: 24567263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biosimilars: How Can Payers Get Long-Term Savings?
    Mestre-Ferrandiz J; Towse A; Berdud M
    Pharmacoeconomics; 2016 Jun; 34(6):609-16. PubMed ID: 26792791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.